Epitelyal over tümörlerinde serum Ca 125 değerlerinin prognostik önemi

Öz

Amaç: Epitelyal över karsinomlarında önemli bir prognostik bilgi olan Serum Ca 125 değerleri tanıda, tedavide ve takipte kullanılabilen bir markerdir. Yaptığımız bu çalışmada seröz ya da müsinöz benign,borderline ve malign över tümörlü olgularda serum Ca 125 değerleri, tümör tipleri arasında bu değerler açısından fark olup olmadığı,borderline,malign tümörlerde prognostik parametre olarak anlamlılığı ve diğerprognostik parametrelerle ilişkisini araştırdık. Materyal ve Metod: 38'i malign, 15'i borderline ve 34'ü benign over tümörü tanısı almış olan toplam 87 olgunun HematoksilenEozin ile boyalı tüm kesitleri ışık mikroskobunda tekrar incelendi ve bu olguların serum Ca 125 değerleri karşılaştırıldı. Benign, borderline ve malign tümörlü olgularındaki serum Ca 125 değerleri karşılaştırılırken laboratuar referens değerlerine göre 35 U/ml üzerindeki değerler(+), altındaki değerler ise (-) kabul edildi. Bulgular: Malign olgularda Ca 125 değerleri ortalaması 1601,28 ± 1996,91, borderline olgularda 64,60 ± 57,30 ve benign olgularda 18,68 ±17,71 olup seröz tumor tipinde 965,78 ± 1744,41 iken müsinöz tümor tipinde 102,97 ± 241,14 'tür. Benign grubunda Ca 125 değeri 35 U/ml'denyüksek (+) olan olguların oranı, borderline ve malign grubundaki olguların oranlarından istatistiksel olarak ileri düzeyde anlamlı farklılık yaratacak şekilde düşüktür (p

Anahtar Kelimeler

• -

Prognostic value of serum Ca 125 levels in ovarian epithelial tumors

Abstract

Prognostic value of serum Ca 125 levels in ovarian epithelial tumors Objectives: As an importantprognostic indicator in epithelial ovarian tumors, serum Ca 125 is a marker which can be used at the diagnosis, treatment andfollow-up. In this study, we investigate the serum Ca 125 levels in either serous or mucinous benign, borderline and malignant ovarian tumors with the respect of their differences between the tumor types, their significance as a prognostic indicator in malignant tumors and relationship with the other prognostic factors. Material and Methods: All H+E slides of 38 malignant, 15 borderline and 34 benign (87 in total) ovarian tumors were re-evaluated at the light microscope and the results were compared with Ca 125 levels of those cases. For the evaluation of the serum Ca 125 levels in benign, borderline and malignant cases, levels above the 35 U/ml as a laboratory reference, were accepted aspositive and negative for the levels below it. Results: Mean Ca 125 levels were 1601.28±1996.91 in malignant, 64.60±57.30 in borderline and 18.68±17.71 in benign cases and as for the histologic types, they were 965.78±1744.41 and 102.97±241.14 for the serous and mucinous tumors, respectively. Percentage of the Ca 125 positive cases (i.e. higher than 35 U/ml) were lower than the percentages of borderline and malignant cases in statisticallyprofoundsignificance (p

Keywords

• -

Kaynakça

1. . Bischof P: What do we know about the origin of Ca 125? Eur J Obstet Gynecol Reprod Biol 1993; 49: 93-98
2. 2. Schwartz MK: Specialized Techniques of Cancer Management and Diagnosis-Section 3: Cancer Markers, Chapter 21. In: Cancer Principles and Practice of Oncology, ed Devita VT, Helman S, Rosenberg SA, J.B. Lippincott Company, Philadelphia, 1993 4 th ed.: 492-574
3. 3. Schultes BC, Whiteside TL: Monitoring of immune responses to Ca 125 with an IFN-g elispot assay. Immunol methods 2003; 279: 1-15
4. 4. Clement PB: Anatomy and Histology of the Ovary, Chapter 15, Diseases of the Peritoneum, Chapter 17, Seidman JD, Russel P, Kurman RJ: Surface Epithelial Tumours of the Ovary, Chapter 18. In: Blausteins Pathology of the Female Genital Tract, ed. Kurman RJ, Springer, 2002 5th ed.:649-675, 729-791, 791-905
5. 5. Rosai J: Female Reproductive System, Chapter 19. In: Ackerman s Surgical 6. Kudoh K, Kikuchi Y Kita T, et al: Preoperative determination of several serum tumour markers in patients with primary epithelial ovarian carcinoma. Gynecol Obstet Invest 1999; 47: 52-57
6. 7. Saygili U, Guclu S, Uslu T, et al: The effect of ascites, mass volume, andperitoneal carcinomatosis on serum Ca 125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer 2002; 12: 438442
7. 8. Engelen MJ, de Bruijn HW, Hollema H, et al: Serum Ca 125 carcinoembryonic antigen, and Ca 19-9 as tumour markers in borderline ovarian tumours. Gynecol Oncol 2000; 78:16-20
8. 9. Wilder JL, PavlikE, StraughnJM, etal: Clinical implications of a rising serum Ca 125 within the normal range in patients with epithelial ovarian cancer:preliminary investigation. Gynecol Oncol 2003; 89: 233-235

9. 10. Ma S, Shen K, Lang J: A risk of malignancy index inpreoperative diagnosis ofovarian cancer. Chin MedJ2003; 116: 396-399